Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidiarrheal rule

This article was originally published in The Tan Sheet

Executive Summary

Relief of travelers' diarrhea is included as an indication for bismuth subsalicylate products in the final monograph for OTC antidiarrheal drug products, effective June 11, FDA reports in the May 12 Federal Register. The condition is described as "a subset of diarrhea occurring in travelers that is most commonly caused by an infectious agent." The approval responds to requests made in response to the 1986 TFM on antidiarrheals (1"The Tan Sheet" April 21, 2003, p. 4). Web materials for Procter & Gamble's Pepto-Bismol already provide information on the condition...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS096817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel